Clinical trial
Phase II Study to Determine Predictive Markers of Response to BMS-734016…
NCT00261365 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00261365 |
|---|---|
| Title | Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010) |
| Official title | An Exploratory Study to Determine Potential Predictive Markers of Response and/or Toxicity in Patients With Unresectable Stage III or IV Malignant Melanoma Randomized and Treated With Ipilimumab (MDX-010/BMS-734016) at Two Dose Levels |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Unresectable Stage III or IV Malignant Melanoma |
| Intervention type | Drug |
| Interventions | Ipilimumab |
| Enrollment | 80 |
| Start date | Nov 1, 2005 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Dec 5, 2005 |
| Last update posted | Sep 29, 2016 |
| Countries | Denmark, Israel, Italy, Norway, Peru, Sweden, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: